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A Novel Gene Amplification Causes Upregulation of the PatAB ABC
Transporter and Fluoroquinolone Resistance in Streptococcus
pneumoniae
Alison J. Baylay,a Alasdair Ivens,b Laura J. V. Piddocka
Antimicrobials Research Group, School of Immunity and Infection, Institute of Microbiology and Infection, and College of Medical and Dental Sciences, University of
Birmingham, Birmingham, United Kingdoma; Centre for Immunity, Infection and Evolution, Ashworth Laboratories, University of Edinburgh, Edinburgh, United Kingdomb
Overexpression of the ABC transporter genes patA and patB confers efflux-mediated fluoroquinolone resistance in Streptococcus
pneumoniae and is also linked to pneumococcal stress responses. Although upregulation of patAB has been observed in many
laboratory mutants and clinical isolates, the regulatory mechanisms controlling expression of these genes are unknown. In this
study, we aimed to identify the cause of high-level constitutive overexpression of patAB in M184, a multidrug-resistant mutant
of S. pneumoniae R6. Using a whole-genome transformation and sequencing approach, we identified a novel duplication of a
9.2-kb region of the M184 genome which included the patAB genes. This duplication did not affect growth and was semistable
with a low segregation rate. The expression levels of patAB in M184 were much higher than those that could be fully explained by
doubling of the gene dosage alone, and inactivation of the first copy of patA had no effect onmultidrug resistance. Using a green
fluorescent protein reporter system, increased patAB expression was ascribed to transcriptional read-through from a tRNA gene
upstream of the second copy of patAB. This is the first report of a large genomic duplication causing antibiotic resistance in S.
pneumoniae and also of a genomic duplication causing antibiotic resistance by a promoter switching mechanism.
Gene amplification, the transient generation of tandem repeatsof large chromosomal regions, is an important source of vari-
ability in bacterial populations.Data from Salmonella suggest that,
in nonselected cultures, transient duplications occur at frequen-
cies of 104 to 102, meaning that 10% to 30% of cells in a non-
selected culture have a duplication somewhere in their genome at
any one time (1). Due to this high prevalence, it is thought that
gene amplification, rather than point mutations, provides a pool
of preexisting variation allowing bacterial populations to adapt to
various stresses, such as antibiotic resistance or growth onunusual
carbon sources (2). However, gene amplification events are diffi-
cult to detect and study, as the tandem repeat units are identical in
sequence and the gene amplifications are often unstable and are
lost by recombination between repeat units once the selective
pressure has been removed.
Streptococcus pneumoniae is the main bacterial cause of com-
munity-acquired pneumonia and represents a major disease bur-
den worldwide (3). Despite the recent introduction of the hep-
tavalent pneumococcal conjugate vaccine, antibiotic resistance is
an increasing problem in this organism due to the spread of mul-
tidrug-resistant clones and increases in antimicrobial resistance
among nonvaccine serotypes (4).
The patA (spr1887) and patB (spr1885) genes, which encode
ABC half transporters, have been associated with the intrinsic re-
sistance of S. pneumoniae to some fluoroquinolone antibiotics.
Each half transporter consists of a nucleotide binding domain and
a membrane-spanning domain, and heterodimerization of PatA
and PatB is required to form a functional transporter (5). Consti-
tutive overexpression of patA and patB has been observed in both
laboratory mutants and clinical isolates and causes decreased sus-
ceptibility to ciprofloxacin and norfloxacin, as well as other
agents, such as dyes and the biocide cetrimide (6–9). In all cases,
patA and patB are coregulated, despite the presence of a degener-
ate transposase gene (spr1886), transcribed in the opposite direc-
tion, separating the two genes. Inactivation of patA or patB either
genetically or using efflux inhibitors results in a hyper-antibiotic-
susceptible phenotype in laboratory mutants (7) and in clinical
isolates increases ciprofloxacin susceptibility even if the isolate
also contains topoisomerase mutations (9).
In addition to transporting fluoroquinolones, recent evidence
suggests that PatAB plays a role in pneumococcal stress responses.
Fluoroquinolone transport is unlikely to be the primary physio-
logical role of PatAB, as fluoroquinolones are synthetic antibiotics
that have been in use for only 30 years. Expression of patA and
patB can be induced by several fluoroquinolones, including those
that are thought not to be substrates for transport, as well as the
nonquinolone DNA-damaging agent mitomycin C (8, 10). This
indicates that PatAB is upregulated as part of a response to DNA
damage. Additionally, overexpression of patA and patB has been
shown to alleviate a fitness cost of linezolid resistance (11), and a
role for PatAB in response to pH stress has been suggested (12).
Despite the potential role of PatA and PatB in pneumococcal
stress responses, no regulatory pathways controlling expression of
patA and patB have been identified. Mutations affecting a Rho-
independent transcriptional terminator upstream of patA were
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shown to cause patAB overexpression in three previous studies
(11, 13, 14). However, mutations affecting this terminator are not
found in all patAB-overexpressing isolates (7, 9), and in these cases
the genetic changes leading to overexpression are unknown.
M184 is a mutant of the unencapsulated laboratory strain R6
(GenBank accession number AE007317.1), characterized previ-
ously by Garvey and Piddock (7). It was generated by exposure of
R6 to the efflux inhibitor reserpine, followed by transformation of
the reserpine-resistant phenotype of one of the selected mutants
back into R6. As well as having reduced susceptibility to reserpine,
M184 was found to be resistant to multiple drugs, including fluo-
roquinolone antibiotics, such as ciprofloxacin and norfloxacin;
the dyes ethidium bromide and acriflavine; and the biocide
cetrimide. Thismultiple-drug-resistance phenotypewas shown to
be due to the increased expression of patA and patB. In this study,
the whole-genome sequences of M184 and three second-genera-
tion transformantswere analyzed to identifymutations thatmight
be responsible for patAB overexpression. This revealed a novel
gene amplification which caused high levels of patAB expression
due to a change in the genomic context of the promoter of the
second copy of patA.
MATERIALS AND METHODS
Bacterial strains and growth. All S. pneumoniae used in this study are
listed in Table 1. All S. pneumoniae strains and isolates were grown stati-
cally at 37°C in an atmosphere of 5% CO2 in brain heart infusion (BHI)
broth (Oxoid, Basingstoke, United Kingdom) or on Columbia agar
(Oxoid, Basingstoke, United Kingdom) supplemented with 5% defi-
brinated horse blood (TCS Biosciences, Buckingham, United Kingdom).
The growth of the strains in broth was assessed by measurement of the
optical density at 660 nm (OD660) of liquid cultures and by viable cell
counts.
Escherichia coli strains used for plasmid construction were grown
overnight on Luria-Bertani (LB) agar at 37°C or in LB broth at 37°C with
shaking at 180 rpm.
DNA extraction, whole-genome sequencing, and data analysis.
Genomic DNA was extracted from all strains using a Wizard Genomic
DNA extraction kit (Promega) following themanufacturer’s instructions.
Genome sequencing was carried out by Genepool (Edinburgh, United
Kingdom) on an Illumina HiSeq sequencing system (Illumina, Saffron
Walden, United Kingdom) according to standard protocols to give
100-bp paired-end reads. Reads were mapped against the published R6
genome sequence (GenBank accession number AE007317.1) using the
Bowtie2 tool (15) and the very sensitive local setting, and a consensus
pileupwas generated using thempileup program from the SAMtools (ver-
sion 0.1.18) suite of programs (16) and the faidx-indexed R6 genome as a
reference. Raw sets of putative single nucleotide polymorphisms (SNPs)
and small insertion or deletion events (indels) were generated frompileup
using BCFtools (version 0.1.17-dev) and filtered to remove variants that
had a quality score of less than 50 and that covered a read depth of less than
50. Identified mutations were confirmed by PCR and Sanger sequencing.
To generate local assemblies, reads meeting the desired criteria were ex-
tracted from the read alignment using SAMtools and assembled with the
Velvet (version 1.1.07) algorithm (17), using the VelvetOptimiser script
by Simon Gladman to determine the optimal parameter settings. Read
alignments were visualized, and the numbers of reads per kilobase per
million readsmapped (RPKM)were calculated using theArtemis (version
14.0.0) sequence viewer (18).
PCR and DNA sequencing. The primer sequences and PCR condi-
tions used in this study are listed in Table 2. PCRs were carried out essen-
tially as described previously (7), although the Extensor PCR master mix
was used to amplify the 9.2-kb duplicated region from strainM184 and its
transformants.
PCR amplimers were sequenced by the Functional Genomics Labora-
tory (School of Biosciences, University of Birmingham, Birmingham,
United Kingdom) as described previously (9).
Transformation. Transformations were carried out as previously de-
scribed (7). Briefly,mid-logarithmic-phase cultures of the recipient strain
were diluted 1:20 in competence medium (Todd-Hewitt broth; Oxoid,
Basingstoke,UnitedKingdom) containing 1mMcalciumchloride (Sigma
Aldrich Ltd., Dorset, United Kingdom), 0.2% bovine serum albumin
(BSA; SigmaAldrich Ltd., Dorset, United Kingdom), and 100 ng/ml com-
petence-stimulating peptide 1 (CSP1; Mimotopes, Clayton, Victoria,
Australia). Donor DNA was added at various concentrations to 500-l
aliquots of a competent cell suspension. Transformation reaction mix-
tures were incubated for 3 h at 37°C, and then 20-l and 200-l volumes
were spread onto selective agar plates. Viable counts were determined in
parallel to allow estimation of the transformation frequency.
Antibiotics and susceptibility determination. The MICs of various
agents for the strains used in this studyweremeasured using the standard-
ized agar doubling dilution method according to the British Society for
Antimicrobial Chemotherapy (19).
TABLE 1 Bacterial strains used in this study
Strain Description
Reference
or source
R6 Unencapsulated wild-type strain derived
from D39
49
M169 Spontaneous reserpine-resistant mutant 7
M184 Reserpine-resistant R6 transformant of
M169
7
R6M184 T1 EtBra-resistant R6 transformant of M184 This study
R6M184 T1 EtBr-resistant R6 transformant of M184 This study
R6M184 T1 EtBr-resistant R6 transformant of M184 This study
M240 R6 patB::magellan2 7
M246 R6 patA::magellan2 7
a EtBr, ethidium bromide.
TABLE 2 Details of PCR primers used in this study
Primer
pair Forward primer sequence Reverse primer sequence Amplicon
1 CTTATTGGTGGGGAGAAGAA GATAACGCGGTTGCAGAAGT Duplication junction
2 GATAGGGCAGAAGAGCATCC GATAACGCGGTTGCAGAAGT Intergenic region between hexA and patA
3 TCTTGCTCAGTCCATCATCGAATAT CAGCATCGGTTCCTTGTC patA copy 1
4 CTTATTGGTGGGGAGAAGAA CAGCATCGGTTCCTTGTC patA copy 2
5 ATGTTGTCCTCGCAGCCTAT CAGCATCGGTTCCTTGTC patA internal region containingmagellan2 insertion
6 TAGTATCGACGGAGCCGATT GCTAGTTGAACGCTTCCATC Cloning site of plasmid pBAV1K2
7 TAAGAATTCTTTAATGAGCGATAGAAGAGTCAG GATAACGCGGTTGCAGAAGT Duplication junction, adding a 5= EcoRI site
(underlined sequence)
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Measurement of intracellular accumulation of ethidium bromide.
The efflux activities of the strains were measured by monitoring the up-
take of ethidium bromide, which fluoresces when intercalated into DNA.
Logarithmic-phase cultures were pelleted by centrifugation at 2,200  g
and resuspended in phosphate-buffered saline (PBS). Cell suspensions
were adjusted to an OD660 of 0.1 with fresh PBS, and 100 l cell suspen-
sion was added in triplicate to a black microtiter tray. Fluorescence was
measured at excitation and emission wavelengths of 530 and 600 nm,
respectively, using a FLUOstar Optima plate reader (BMG Labtech, Ay-
lesbury, United Kingdom) every 2 min for a total of 30 min. A final con-
centration of 100 M ethidium bromide was added to each well by injec-
tion on the second cycle of measurement.
Measurement of expression of patA and patB. RNA was extracted
from three biological replicates of each strain to be tested using a Promega
SV total RNA isolation kit according to the manufacturer’s instructions
(Promega, Southampton, United Kingdom). RNA and contaminating
DNA concentrations were determined using a Qubit fluorimeter (Life
Technologies, Paisley, United Kingdom). Residual DNA contamination
was removed by treatment with Turbo DNase (Life Technologies), and
cDNA was generated using SuperScript III reverse transcriptase (Life
Technologies) following the first-strand synthesis protocol supplied by
the manufacturer. Expression of patA and patB relative to the expression
of rpoB was measured by quantitative real-time PCR by monitoring the
fluorescence of SYBR green dye. Reactionmixtures consisted of 12.5l IQ
SYBR green supermix (Bio-Rad, Hemel Hempstead, United Kingdom),
375 nM (each) forward and reverse primers, and 1 l cDNA in a 25-l
reaction mixture. Real-time PCR was carried out using a Bio-Rad CFX96
thermal cycler with the following protocol: 3 min at 95°C, followed by 40
cycles of 10 s at 95°C and 30 s at 54.5°C. Expression values were calculated
from the fluorescence data using the Pfaffl method (20).
Insertional inactivation of individual copies of patA in M184. An
internal region of patA containing the magellan2 minitransposon from
strain M246 (R6 patA::magellan2) was amplified by PCR using primer
pair 5 (Table 2). The PCR amplimer was diluted 1:10 six times, and 10 l
of each concentration was transformed into M184 as described above.
Transformants were selected on 100 mg/liter spectinomycin to select for
successful incorporation of the minitransposon which contains a specti-
nomycin resistance gene, aad9. Primer pairs specific for the N-terminal
half of each copy of patA were used to determine which copy of patA
contained the insert.
Growth kinetics and determination of stability of gene amplifica-
tion. To measure growth kinetics, a 1% inoculum of the strain of interest
was added to 50ml BHI broth. Growth was monitored at hourly intervals
by measurement of the OD660 for 8 h.
To measure the stability of the gene amplification, M184 cultures were
grownovernight in triplicateon8mg/liter ethidiumbromide to select for cells
containing the duplication. Cells were scraped directly off the plates, resus-
pended in BHI broth containing 10% glycerol, and stored at80°C. These
time zero cultures were then diluted 1:1,000 in fresh BHI broth and grown
exponentially without selection for 12 h (corresponding to approximately 15
generations). Samples of culture from 0 and 12 hwere serially diluted in PBS
and grown on nonselective agar to obtain single colonies. For each biological
replicate and time point, 20 colonies were picked at random and restreaked
ontobothnonselective agar andplates containing 8mg/liter norfloxacin.The
proportions of colonies retaining norfloxacin resistance at 0 and 12 h were
compared to calculate the probability of loss of the duplication using the
following equation. Assuming that at each generation a proportion (p) of the
population loses the duplication, the proportion of cells retaining the dupli-
cation after n generations is (1  p)n (21). To confirm that the loss of
norfloxacin resistance correlated with loss of the duplication, DNA was ex-
tracted from a representative sample of candidate colonies and checked for
the presence of the duplication junction by PCR.
Construction of pBAV1K2 reporter plasmid, cloning of patA pro-
moter and tRNA gene, and reporter assay. To generate plasmid
pBAV1K2, plasmids pBAV1K-T5-gfp (22) and pMW82 (23) were di-
gested with EcoRI and PstI (Thermo Scientific), and digestion products
were separated on a 1% agarose gel. The 2,800-bp plasmid backbone of
pBAVK1K-T5-gfp and the 824-bp band corresponding to the gfp gene of
pMW82 were extracted from the gel using a Qiagen gel extraction kit
according to the manufacturer’s instructions. The DNA fragments were
ligated using QuickStick ligase (Bioline) and used to transform E. coli
TOP10 cells (Life Technologies). Transformants were selected on 50 mg/
liter kanamycin. To remove DNAmethylation for subsequent digestions,
the extracted plasmidwas transformed intoE. coli JM110 chemically com-
petent cells (kindly provided by Yanina Sevastsyanovich) and reextracted.
To clone the patA promoter into pBAV1K2, giving pBAV1K2p, a
144-bp DNA fragment that covered the region from 12 to 146 bp up-
stream of the patA start codon and incorporated a 5= EcoRI site and a 3=
XbaI site was synthesized by GeneArt (Life Technologies). The promoter
fragment was digested with EcoRI and XbaI, purified using a QIAquick
PCR purification kit (Qiagen), and combined in a 100:1 ratio with
pBAV1K2 DNA linearized with XbaI and EcoRI. The DNA fragments
were ligated with QuickStick ligase and used to transform E. coli TOP10
cells. Transformantswere selected on 50mg/liter kanamycin and screened
for successful incorporation of the insert by PCRwith primer pair 6 (Table
2). To clone the tRNA-Glu gene upstream of the patA promoter, giving
plasmid pBAV1K2tp, a naturally occurring SpeI site 134 bp upstream of
the patA start codon was exploited. A 681-bp region spanning the dupli-
cation junction in M184 was amplified using primer pair 7 (Table 2),
which introduces a 5= EcoRI site. This was digested with EcoRI and SpeI
and combined in a 100:1 molar ratio with EcoRI- and SpeI-linearized
pBAV1K2p. Ligation, transformation, transformant selection, and PCR
screening were performed as described above.
Plasmid DNA was extracted from E. coli cells using a QIAquick mini-
prep kit according to the manufacturer’s instructions, and 20 l of each
plasmid preparationwas used to transform S. pneumoniaeR6 as described
above. Successful transformants were selected on plates containing 100
mg/liter kanamycin.
R6 cells containing pBAV1K2, pBAV1K2p, or pBAV1K2tpwere grown
in triplicate in BHI broth supplemented with 100 mg/liter kanamycin to
an OD660 of 0.5. One milliliter of each culture was transferred to a micro-
centrifuge tube, and cells were harvested by centrifugation (14,000 g, 2
min). Cells were resuspended in 200 l sterile PBS and transferred to a
black microtiter tray. Fluorescence was measured using a FLUOstar Op-
tima plate reader (BMG Labtech) with excitation and emission wave-
lengths of 492 and 520 nm, respectively.
RESULTS
Overexpression of patAB can be transferred fromM184 toR6 in
a single transformation step. To identify the mutation responsi-
ble for increased expression of patA and patB in M184, the ge-
nome sequences of M184 and our laboratory stock of R6 were
determined by Illumina sequencing. Reads were aligned against
the published R6 genome sequence to identify single nucleotide
polymorphisms (SNPs) and small insertion or deletion events (in-
dels). This analysis identified 27 point mutations and small indels
present in M184 that were not found in R6 (see the supplemental
material at http://epapers.bham.ac.uk/1958/). Exclusion of reads
that mapped to more than one position in the genome did not
change the set of variants identified (data not shown).
To separate mutations causing patAB overexpression from
compensatory mutations and bystander mutations, M184 DNA
was transformed into R6 and transformants were selected on 8
mg/liter ethidium bromide. Reserpine was not used to select
transformants, as the mechanism of resistance to this agent
appears to be more complex; inactivation of patA increased sus-
ceptibility to reserpine, but inactivation of patB did not (7). To
avoid selecting fluoroquinolone-resistant topoisomerase mu-
tants, ethidium bromide, another substrate of the PatAB trans-
Baylay et al.
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porter, was used to select transformants that had incorporated
mutations causing patAB overexpression. Ethidium bromide-re-
sistant transformants were selected in a single step, but at a trans-
formation frequency of 106 to 107, 10- to 20-fold lower than
that for transformants transformed with a spectinomycin resis-
tance cassette under the same conditions. No spontaneous
ethidium bromide-resistant mutants were selected on DNA-free
control plates.
Three transformants, named R6M184 T1, R6M184 T2, and
R6M184 T3, were chosen at random for further study. Expression
of patA and patB in all three transformantswasmeasured by quan-
titative real-time PCR to confirm successful transfer of the patAB
overexpression phenotype. In M184 and all three transformants,
both genes were expressed at a level 100 to 1,000 times higher than
that in R6 (Fig. 1A).
The phenotypes of M184 and the three transformants were
compared to confirm that the upregulation of patAB observed in
the transformants conferred a phenotype similar to that of M184.
First, the MICs of ciprofloxacin, norfloxacin, and ethidium bro-
mide for R6, M184, the three transformants, and M240, an R6
derivative where patB has been inactivated by insertion of a ma-
gellan2 minitransposon (7), were determined in the presence or
absence of the ABC efflux pump inhibitor sodium orthovanadate.
As expected,M184 and the three transformants showed decreased
susceptibility to all three agents compared to that of R6 andM240,
and this was reversible by addition of sodium orthovanadate (Ta-
ble 3).However, the transformants differed slightly fromM184, in
that addition of sodium orthovanadate appeared to increase sus-
ceptibility to norfloxacin to a greater degree (at least 2 dilutions) in
the transformants than in M184.
Second, the accumulation of ethidium bromide by R6, R6
patB::magellan2, M184, and the three transformants was also
measured. After 10 min, all three transformants accumulated sig-
nificantly lower levels of ethidium bromide than R6 (1.4- to 1.6-
fold reduction compared to the level of accumulation for R6; P
0.05; Fig. 1B). However, the decrease in ethidium bromide accu-
mulation in the transformants was less pronounced than that in
M184, which accumulated 2.6-fold lower levels of ethidium bro-
mide than R6.
Comparison of R6, M184, and transformants by whole-ge-
nome resequencing reveals a novel gene amplification. To iden-
tify which mutation or combination of mutations was transferred
from M184 to the three transformants to give patAB overex-
pression, the whole genomes of the transformants were se-
quenced by Illumina sequencing. Reads were aligned against
the published R6 genome, and SNPs and small indels were
identified as described above. Six mutations were found in
transformant 1, three were found in transformant 2, and nine
were found in transformant 3 (http://epapers.bham.ac.uk/195
8/). Unexpectedly, however, there were no mutations shared
between M184 and the three transformants, indicating that
none of the 27 mutations found in M184 were the cause of
patAB overexpression. This was confirmed by PCR and Sanger
sequencing of all candidate mutations. It was then hypothe-
sized that patAB overexpression was caused by a genomic rear-
rangement larger than that which is detectable using the SNP-
calling approach. This was investigated in two ways.
First, the alignment of the reads against the R6 genome was
examined for evidence of genomic rearrangements by identifying
clusters of reads that did not align as proper pairs. Proper pairs are
defined as reads aligning both within 250 bp of each other and in
the correct relative orientation. Illumina sequence reads aligned
against the published R6 genomewere filtered to exclude all prop-
erly paired reads. Visual inspection of the filtered alignment iden-
tified a region with a high density of improperly paired reads up-
stream of patA in M184 and the transformants that was not
present in R6 (Fig. 2a). The pairs of these reads were extracted
FIG 1 Expression of patA and patB and accumulation of ethidium bromide in
M184 andR6M184 transformants. (A) Expression of patA (black bars) and patB
(gray bars) relative to that of rpoB. (B) Accumulation of ethidium bromide
after 10 min of incubation with 100 M ethidium bromide. *, accumulation
significantly lower than that of R6 (P 0.05).
TABLE 3 MICs of ciprofloxacin, norfloxacin, and ethidium bromide for
four R6M184 transformants in the presence and absence of sodium
orthovanadate
Strain
MICa (mg/liter)
Cip
Cip
NaO Nor
Nor
NaO EtBr
EtBr
NaO
R6 0.5 0.25 1 1 2 1
M184 2 0.5 8 2 16 1
R6M184 T1 2 0.25 8 1 16 1
R6M184 T2 2 0.25 8 1 16 1
R6M184 T3 2 0.25 8 1 16 1
a Cip, ciprofloxacin; Nor, norfloxacin; EtBr, ethidium bromide; NaO, 50 M sodium
orthovanadate. MICs are the modes from at least three independent experiments. Bold
text indicates MICs that are 2 or more dilutions greater than the MIC for R6.
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from the raw data files by matching read names and realigned to
the published R6 genome. They aligned to four regions of the
genome, corresponding to an area just upstream of each of the
four copies of the rRNA genes. A local assembly generated from
these read pairs resulted in a single contig of 608 bp. This was used
as a query sequence to search the published R6 genome sequence.
Hits were found between the 3= 326 bp of the contig and regions
upstream of the rRNA loci, with the closest matches being with
copies 2 and 4 (Fig. 2b). The remaining 282 bpmatched to a region
encompassing a region 183 to 464 bp upstream of patA. This sug-
gested that a genomic rearrangement involving the patA region
had occurred.
Second, to look for evidence of changes in copy number of
parts of the genome, normalized read depths, expressed as the
number of reads per kilobase per million reads mapped (RPKM),
were calculated for each annotated coding sequence (CDS) of
more than 200 bp from the read alignments from each strain, and
the profiles from M184 and the three transformants were com-
pared against the profile from R6 (Fig. 3). This analysis identified
six genes that had significantly higher read depths inM184 and the
three transformants than in R6 (P  0.05, one-tailed Student’s t
test). These genes were contiguous and corresponded to spr1880
to spr1887 (spr1883 was not included in the analysis, as it is less
than 200 bp in length). The average RPKM ratio for these genes
relative to that for R6 was 1.2 (standard deviation 0.4) across all
four patAB-overexpressing strains, whereas it was 0.6 (standard
deviation  0.1) for the rest of the tested CDSs. This region en-
compassed patA (spr1887) and patB (spr1885), and the final gene
in the region, spr1880, is located directly upstream of the fourth
rRNA locus. Taken together, these results suggest that a 9.2-kb
region of the genome containing patA and patBhas been tandemly
duplicated in M184 and the three transformants.
To confirm the duplication suggested by the genome sequence
analysis, PCR primers were designed to amplify the predicted
novel junction between the two duplicated copies. PCR am-
plimers were obtained when DNA fromM184 or the three trans-
formants was used as a template but not when R6 DNA was used
(http://epapers.bham.ac.uk/1958/). The sequences of the result-
ing PCR amplimers were determined and confirmed to be the
same as the sequence of the contig assembled from the improperly
paired reads.
To confirm that the two copies of the locus were arranged in
tandem, a second PCR was carried out using primers specific for
the 5= end of patA and the 3= end of the upstreamgene hexA, which
is not part of the duplication. In R6, these primers amplify the
expected 357-bp region between patA and hexA. However, when
FIG 2 Evidence of genomic rearrangements from improperly paired reads. (a) Depth of reads aligned to the hexA and patA region following removal of properly
paired reads by filtering for M184 (solid line) and R6 (dashed line). The y axis indicates read depth of improperly placed reads. (b) Matches found by a BLAST
search between a contig assembled from improperly paired reads and the R6 genome.
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DNA from M184 or the three transformants was used as a tem-
plate and the PCR extension time was increased to 10 min, a sec-
ond PCR amplimer of approximately 9 kb was observed (http:
//epapers.bham.ac.uk/1958/). This corresponds to amplification
from the patA primer binding to the second copy of patA; it was
absent when R6 DNA was used as a template.
The gene amplification does not affect growth and has a low
segregation rate.The generation times of R6,M184, and the three
transformants were measured during growth in liquid medium.
M184 had a significantly longer generation time than R6 (46 4
min compared to 34 2min; P 0.05), but no significant growth
defect was observed in the three transformants. This implies that
carriage of the duplication itself does not affect the growth of R6 in
liquid medium. We hypothesize that the growth of M184 is im-
paired because of one or more of the other mutations that it car-
ries. For example, mutations were found in genes encoding pro-
teins involved in key cellular processes, such as the translation
factor EF-Tu (http://epapers.bham.ac.uk/1958/).
Large genomic duplications are often unstable, as recombina-
tion between the two copies of the duplicated locus can cause loss
of the intervening DNA (2). The rate of loss of the duplication
fromM184 and the transformantswasmeasured during growth in
liquid medium in the absence of antibiotic. Following 12 h of
exponential-phase growth in BHI broth without antibiotic,
72% 11% of the colonies tested had lost resistance to norfloxa-
cin, suggesting a probability of loss per cell per generation of
FIG 3 Evidence of duplication of a genomic region, including patA and patB, from comparison of per gene normalized read depths. (a) Per gene RPKM values
for M184 plotted against those for R6. Six genes (filled circles) appeared to be present at a higher copy number than the remaining genes (gray crosses) in M184
than in R6. On further inspection, these genes were contiguous and included patA and patB (indicated). The hexA gene immediately upstream of patA (filled
triangle) was not included in the higher-copy-number region. (b) The same six genes were present at increased copy numbers in M184 and the three R6M184
transformants (T1 to T3). The slope of the regression line calculated for the high-copy-number genes (upper) was divided by the slope of the regression line for
the remainder of the genome (lower) to obtain an estimate of the copy number of the amplified genes.
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0.018  0.008 (n  8). To confirm that the loss of norfloxacin
resistance correlated with the loss of the duplication, seven nor-
floxacin-sensitive and seven norfloxacin-resistant colonies were
tested by PCR for the presence of the duplication junction. PCR
amplimers corresponding to the duplication junction were ob-
tained from all seven of the resistant colonies but none of the
sensitive colonies.
On the basis of these observations and under the assumption
that continuous exponential growth occurs at a rate equivalent to
that for R6 (generation time, 34 min), the proportion of cells
carrying the duplication would drop below the detection limit of
this experiment (5%) after 2.5 to 7 days.
The duplication mechanism is unknown. To determine the
mechanism of gene amplification in M184, 50-bp sequences on
either side of the start point and endpoint of the duplication and
the duplication junction were aligned and examined for the pres-
ence of repeat sequences. When comparing the start point and
endpoint of the duplication, no obvious repeat sequences were
found. Only two identical bases (TA) were precisely conserved
between the start and end of the duplication, and there were only
7 identical bases in total in the 20-bp region surrounding the join
point (http://epapers.bham.ac.uk/1958/). Duplication of the re-
gion results in duplication of the conserved TA motif at the junc-
tion point, but introduction of gaps into the alignment to take this
into account still did not reveal any larger conserved repeat se-
quences (data not shown).
Interestingly, the 9 bp of sequence on either side of the end-
point of the duplication formed a nearly perfect inverted repeat
with only one mismatch (CTACAACAT-AAGTTGTAG). How-
ever, this sequence was not present in the sequence around the
start of the duplication or at the duplication junction. The Reg-
TransBase database of prokaryotic cis-regulatory elements (24)
was searched for motifs similar to this inverted repeat using the
STAMP motif alignment tool (25), but no matches were found.
Illegitimate end joining by DNA gyrase has been implicated in
the formation of some gene amplifications, so the duplication
start point and endpoint were examined for similarity to known
pneumococcal DNA gyrase and topoisomerase IV cleavage site
consensus sequences previously reported (26). No convincing
matches were found.
M184 also overexpresses guaA but not the other duplicated
genes. As well as patA and patB, the 9-kb duplicated region con-
tains six other protein-coding genes and a tRNA gene, represented
in Fig. 4A. The expression levels of five of these, spr1886, guaA
(spr1884), gpi (spr1882), gltX (spr1881), and spr1880, from R6,
M184, and the three transformants weremeasured by quantitative
reverse transcription-PCR (qRT-PCR). In M184 and the three
transformants, guaAwas expressed at a level 20- to 50-fold higher
than the level of expression in R6. This gene encodes a type 1
glutamine amidotransferase enzyme (NCBI conserved domain
cd01745). Approximately 7-fold higher levels of transcript were
observed in M184 for the degenerate transposase gene spr1886,
which is located between the patA and patB genes in the opposite
orientation. There was no difference in expression for any of the
other tested genes (Fig. 4B). The expression levels of the tRNA
gene could not be measured, as five copies of this gene exist in the
R6 genome, meaning that unique primers could not be designed.
Overexpression of patA and patB in M184 comes from the
second copy of the locus. Duplication of patA and patB did not
fully explain the very high levels of patAB overexpression mea-
sured by qRT-PCR in M184 and the three transformants. Wild-
type levels of expression from two identical gene copies could
theoretically result in a 2-fold increase in expression, but instead,
large (100- to 1,000-fold) increases in expression were observed.
There are two possible explanations for this observation. First,
the duplication changes the genetic context of the second copy of
patA and patB, which may result in increased expression of these
genes due to the loss of regulatory control. Second, and alterna-
tively, both copies of patA and patB could be overexpressed due to
a positive-feedback loop if the initial increase of expression due to
the duplication itself is sufficient to increase PatAB levels above a
threshold value. If the first hypothesis is correct, inactivation of
the first copy of patA should have no effect on the phenotype of
M184, while inactivation of the second copy should reduce the
level of efflux (and increase accumulation) to that for R6. On the
other hand, if the second hypothesis is correct, inactivation of
either copy of patA would reverse antibiotic resistance in M184.
To test this, M184 cells were transformed with donor DNA
amplified from M246, a strain of R6 where patA is inactivated by
insertion of the magellan2 minitransposon (7). The donor PCR
amplimer contained the mariner minitransposon flanked by an
internal patA sequence, meaning that recombination with either
copy of patA in M184 should be equally likely. It is known that
multiple recombination events can occur simultaneously in one
pneumococcal cell (27), so to select transformants where only one
copy of patA was inactivated, cells were transformed with a series
of dilutions of the PCR amplimer and candidates were selected
from the lowest donor DNA concentration that produced viable
colonies. It was expected that roughly equal numbers of transfor-
mants with the transposon inserted in each copy of patAwould be
obtained.However, a total of 52 spectinomycin-resistant transfor-
mants were obtained from three separate experiments, and all
contained the magellan2 transposon inserted in the first copy of
patA. Three transformants containing the insertion in copy 1 of
patAwere selected at random for further testing. TheMICs of cip-
rofloxacin, norfloxacin, and ethidiumbromideweremeasured for
these strains in the presence and absence of sodium orthovana-
date. The MICs obtained for all three strains were identical to
those for M184, suggesting that inactivation of the first copy of
patA in M184 does not abolish PatAB overexpression.
Overexpression from copy 2 of the patAB locus could be
caused by read-through from a tRNA gene. To determine why
the second copy of patA appeared to contributemore to theM184
phenotype than the first copy, the genomic context of the second
copy of patA was examined. The duplication results in the start
codon of the second copy of patA being located 365 bp down-
stream of one of the five copies of a glutamate-specific tRNA gene
found in the R6 genome. A list of S. pneumoniae transcriptional
terminator predictions made by the TransTermHP program (28)
was examined, and no Rho-independent terminator predictions
were found in the downstream region of the tRNA gene. This
suggested that increased expression of the second copy of the
patAB locus could be conferred by transcriptional read-through
from the tRNA gene. To test this prediction, a promoter probe
plasmid was constructed by replacing a T5 promoter-gfp cassette
from the broad-host-range plasmid pBAV1K-T5-gfp (22) with a
promoterless gene coding for an unstable green fluorescent pro-
tein (GFP) variant from plasmid pMW82 (23), generating vector
pBAV1K2. Unstable GFP was used to prevent changes in expres-
sion of GFP from the tested promoter from being obscured by
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fluorescence from accumulated stable GFP. Two different DNA
fragments were cloned upstreamof the promoterless gfp (Fig. 5A).
The first contained the predicted patA promoter alone
(pBAV1K2p), while the second, larger region spanned the M184
duplication junction from the end of copy 1 of spr1880 to the start
of copy 2 of patA and contained the tRNA gene upstream of the
patA promoter (pBAV1K2tp).
The promoter constructs were transformed into R6, and
GFP fluorescence was measured during mid-logarithmic-phase
growth (Fig. 5B). The fluorescence from pBAV1K2p was 2.4-fold
higher than that from R6 harboring the empty pBAV1K2 vector
(574  132 and 236  104 fluorescence units, respectively). The
fluorescence levels observed for pBAV1K2tp were 6.3-fold higher
than those observed for the patA promoter alone (3,682  327
fluorescence units). However, this may be an underestimate of
true promoter activity, as this strain had a severe growth defect
compared to the growth of R6 containing pBAV1K2 or
pBAV1K2p (generation times, 56 min and 35 min, respectively).
Although it could not be confirmed, this may be a side effect of
GFP toxicity.
DISCUSSION
Overexpression of patA and patB confers clinically relevant resis-
tance to fluoroquinolone antibiotics (9). InM184, overexpression
of the patA and patB genes was conferred by a duplication of a
9.2-kb section of the genome and not a point mutation. To our
knowledge, this is the first example of a large (	1-kb) gene am-
plification in S. pneumoniae. The only previously reported in-
stance was an 18-bp duplication of a ribosome binding site in the
ermA gene which caused macrolide resistance (29). Gene amplifi-
cations resulting in antibiotic resistance have been observed in
several bacterial species and have been reviewed elsewhere (30).
Gene duplications can form by RecA-dependent and -inde-
pendent mechanisms. RecA-dependent duplications are formed
by homologous recombination between long repeats, where 25 to
40 nucleotides of sequence identity is required (31, 32). Common
manifestations of this are recombinations between rRNA operons
or insertion sequence elements (1, 33). Two mechanisms have
been proposed to explain RecA-independent duplications. The
first is strand slippage during rolling-circle DNA replication,
which requires short areas of sequence identity (34). The second is
FIG 4 Measurement of expression of genes contained within the duplicated region of M184. (A) Representation of the genomic region around patA and patB.
Dotted lines represent the extent of the duplicated region in M184 and the three transformants. (B) Expression of seven genes contained within the duplication
measured by qRT-PCR from R6 (black bars) and M184 (white bars). Error bars represent the standard deviations from three biological replicates.
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illegitimate end joining during repair of double-stranded DNA
breaks catalyzed by DNA gyrase (35). This does not require se-
quence homology at the duplication ends (36). No direct repeats
were found at the ends of the duplicated region inM184, suggest-
ing that the formation of this duplication is likely to be due to
illegitimate end joining. Expression of patAB has previously been
shown to be induced by fluoroquinolones and mitomycin C,
which are DNA-damaging agents (8, 10). It is tempting to specu-
late that this could have been due to transient duplication pro-
moted by DNA gyrase inhibition.
Similar homology-independent duplication junctions were
previously observed in a study of 104 amplification mutants of
Acinetobacterwith an increased ability to grow on benzoate, where
36 of 104 distinct duplication junctions identified showed no se-
quence identity at the join point (37). Several of these homology-
independent duplicationswere identified inmultiple independent
mutants, suggesting that homology-independent duplications
can be formed in a site-specific manner. This could be explained
by site specificity in DNA gyrase cleavage sites, as it has previously
been shown that DNA gyrase cleaves preferentially at certain sites
(38). In M184 the sites upstream and downstream of the duplica-
tion did not match the reported S. pneumoniae DNA gyrase con-
sensus cleavage site (26). However, gyrase cleavage sites are highly
degenerate, so the possibility of site-specific gyrase cleavage can-
not be completely ruled out. It has also been suggested that site
specificity in the formation and deletion of tandem repeats could
be mediated by the DNA secondary or tertiary structure promot-
ing recombination between particular sites through protein-pro-
tein or protein-DNA interactions (37, 39, 40). It is interesting that
there is an inverted repeat motif at the 3= end of the duplicated
region that could be a binding site for an unknown protein factor.
Following an initial tandem duplication event, further gene
amplification can occur by RecA-dependent homologous recom-
bination between copies of the duplicated locus or by rolling-
circle replication mechanisms (30). In several previous studies of
adaptive gene amplification, observed copy numbers were greater
than 2, indicating that further amplification has taken place. In
Salmonella enterica, 5- to 40-fold amplification of genes encoding
initiator tRNAswas shown to alleviate a fitness cost of resistance to
peptide deformylase inhibitors (41). A 5-fold amplification of the
blaA gene caused ampicillin resistance in Yersinia enterocolitica
(42). In the Acinetobacter baumannii study described above, mu-
tants with an increased ability to grow on benzoate were found to
possess between 3 and 45 copies of the cat genes (37). Additionally,
in a recent study, 10- to 110-fold amplifications of a Tn6020 trans-
poson containing an aminoglycoside resistance gene were shown
to be the cause of tobramycin treatment failures in A. baumannii
clinical isolates (43). A 4-fold amplification of the folCEPBK genes
was found in Streptococcus agalactiae and resulted in decreased
susceptibility to sulfonamides and trimethoprim (21). In these
cases, the adaptive benefit of the amplificationwas either shownor
assumed to be linked to the copy number of the amplified genes.
Further amplification of the duplicated region has not oc-
curred in M184, and the copy number is therefore only 2. How-
ever, this duplication results in a level of expression of patA and
patB much higher than that which can be explained by increased
gene dosage alone. Insertional inactivation of the first copy of patA
had no effect on the antibiotic resistance phenotype, indicating
that the increased production of PatABoriginates from the second
copy of the locus. The duplication event alters the genomic con-
text of the second copy of patAB and brings it under the control of
the promoter of a tRNA gene.
Therefore, in contrast to previous studies, although the adap-
tive mutation in this strain is a gene amplification, the primary
cause of the increased antibiotic resistance is altered expression of
the patAB locus, rather than increased gene dosage. Antibiotic
resistance mediated by promoter switching caused by a gene de-
letion event has been previously identified (44). However, to our
knowledge, this is the first observation of a transient gene dupli-
cation causing antibiotic resistance due to placing resistance genes
under the control of a highly active promoter. In the sulfonamide-
and trimethoprim-resistant S. agalactiae isolate (21), expression
of the second, third, and fourth copies of the fol genes was ascribed
to an alternative promoter, but this led to only a 5-fold increase in
gene expression, rather than the 4-fold increase that would be
expected from gene dosage alone.
Most gene duplication events are unstable and are lost in the
absence of selection due to recombination between identical cop-
ies of the locus (2). Typical segregation rates range from 0.01 to
0.15 loss events per cell per generation (2), although the 13.5-kb
quadruplication event causing sulfonamide and trimethoprim re-
sistance in S. agalactiae was highly stable and lost at a rate of only
0.003 per cell per generation (21). The duplication observed in
M184 was unstable, as expected, and lost at an estimated rate of
between 0.01 and 0.03 per cell per generation. Although this does
not approach the level of stability observed in the S. agalactiae
FIG 5 Measurement of activity of the patA promoter with and without the
tRNA gene found upstream of patA copy 2 in strains containing the duplica-
tion. (A) Representation of the cloning of the tRNA gene and patA promoter
upstream of a promoterless gfp gene in vector pBAV1K2. (B) Fluorescence
levels measured from R6 cells containing pBAV1K2 (Empty vector),
pBAV1K2p (p), and pBAV1K2tp (tp). Error bars represent the standard devi-
ations from three biological replicates. *, fluorescence significantly greater
than that from pBAV1K2p (P 0.05, one-tailed Student’s t test).
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strain, this is still toward the more stable end of the range of pre-
viously observed segregation rates. The observed rate of duplica-
tion loss suggests that the duplication would be undetectable by
themethod used here within 2.5 to 7 days; however, this is assum-
ing continuous exponential growth under laboratory conditions,
whereas growth in a physiological situation may be limited by a
number of factors. Therefore, it is possible that the stability of this
duplication and, therefore, the increased expression of patAB
could be higher in an environment in which antibiotics are used.
Overexpression of guaA, which is adjacent to patB in the S.
pneumoniae genome, was also observed in M184 and the three
transformants. This gene encodes a type 1 glutamine amidotrans-
ferase enzyme, which is one of a diverse family of enzymes cata-
lyzing the transfer of ammonia from glutamine to a variety of
substrates (45). However, overexpression of guaA was not ob-
served in previous studies where expression of this gene was mea-
sured either as part of a global transcriptome analysis (10) or di-
rectly by qRT-PCR (46). The gene was overexpressed to a lesser
extent than patA and patB (20- to 50-fold for guaA compared to
100- to 1,000-fold for patA and patB), so it is unclear whether this
shows that guaA is coexpressed with patAB on a single transcript
or whether the observed overexpression is due to leaky termina-
tion of transcription from patB. However, overexpression of
patAB has been linked to DNA damage (8), and glutamine ami-
dotransferases are known to be involved in nucleotide biosynthe-
sis pathways (47); a functional link is therefore possible. The gpi,
gltX, and spr1880 genes downstream of guaA were not upregu-
lated in this study. Promoter prediction software (48) suggests the
presence of a promoter sequence upstream of these genes (data
not shown), so it is likely that they are expressed on at least one
separate transcript.
The data presented here represent the first report of a large
gene amplification in S. pneumoniae causing antibiotic resistance.
This is also the first time that capture of a resistance gene by a
strong promoter due to transient gene amplification has been ob-
served. Taken together, these results add to the growing body of
evidence suggesting that gene amplification is an important adap-
tive mechanism in bacteria allowing them to survive antibiotic
exposure.
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